Effects of β-blocker therapy in pulmonary arterial hypertension patients: propensity-adjusted outcome analysis
| Unadjusted | Optimal matching | |
| Mortality OR (95% CI) | 1.11 (0.75–1.66) | 1.13 (0.69–1.82) |
| Clinical worsening events OR (95% CI) | 1.01 (0.64–1.60) | 0.96 (0.55–1.68) |
| Transplant OR (95% CI) | 1.02 (0.46–2.23) | 1.17 (0.39–3.47) |
| Hospitalisation OR (95% CI) | 0.89 (0.60–1.32) | 1.06 (0.66–1.32) |
| NYHA class change from baseline | ||
| Year 1 | -0.12 (-0.35–0.10) | 0.03 (-0.24–0.30) |
| Year 3 | 0.11 (-0.53–0.31) | 0.07 (-0.53–0.40) |
| Year 5 | 0.24 (-0.01–0.49) | 0.17 (-0.15–0.48) |
| 6MWD m | ||
| Baseline | -15 (-42–12) | -3 (-36–30) |
| Follow-up | -15 (-50–20) | -23 (-69–22) |
Data are presented as mean difference (95% CI), unless otherwise stated. NYHA: New York Heart Association; 6MWD: 6-min walking distance.